Author Page for Qing Zhou

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Number of pages: 29 Posted: 06 Dec 2018

Qing Zhou, Xiao-Qing Liu, Pei Hu, Jian-Ying Zhou, Li Zhang, Tong-Tong An, Lin Wu, Ying Cheng, Ji Jiang, Zhi-Hong Chen, Bin Gan, Wan-Hong Xu, Feng R Luo, Li Xu, Xiao Xu and Yi-Long Wu

Government of the People's Republic of China - 307th Hospital, Government of the People's Republic of China - 307th Hospital, Chinese Academy of Medical Sciences, Zhejiang University, Chinese Academy of Medical Sciences, Central South University, Peking University - Cancer Hospital and Institute, Jilin Provincial Cancer Hospital, Chinese Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Pharmaceutical Research, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc. and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

Downloads 54 (681,443)

Qing Zhou

Government of the People's Republic of China - 307th Hospital

1

54

0

0

Scholarly Papers (1)

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Abstract: